Loading...
•
Jun 30, 2020
Amicus Therapeutics Q2 2020 Earnings Report
Announced second quarter 2020 financial results and corporate updates.
Key Takeaways
Amicus Therapeutics announced financial results for the second quarter ended June 30, 2020, reporting Galafold 2Q2020 Revenue of $62.4 Million and is on track to achieve 2020 Revenue Guidance of $250M-$260M. The Company also summarized recent program updates and reiterated its full-year 2020 guidance.
Galafold 2Q2020 Revenue of $62.4 Million
On-Track to Achieve 2020 Revenue Guidance of $250M-$260M
AT-GAA Phase 3 PROPEL Study Readout and Rolling BLA Submission to U.S. FDA on Schedule
Advancing Industry-Leading Rare Disease Gene Therapy Portfolio
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics Revenue by Segment
Revenue by Segment
Galafold Revenue
CapyFin.com Forward Guidance
Amicus is on track to achieve its 2020 key strategic priorities, including its global Fabry launch, Pompe late-stage development program, and advancing its industry-leading gene therapy pipeline and is firmly on a path to profitability without the need to access the equity markets.